产品详情
- Genetically modified cell lines best reflect MOA (Mechanism of Action)
- Higher activity and larger assay window for robust and reproducible cell-based bioassay
- Comprehensive application data to support assay development and validation
- Full tracible record, stringent quality control and validated cell passage stability
- Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
- Global commercial license assistance whenever regulatory filing is required
描述(Description)
The Human GLP-1R (Luc) HEK293 Reporter Cell was engineered to not only express CREB signaling response element, but also express the receptor full length human GLP-1R (Gene ID: 2740), which can drive luciferase expressing systems by GLP-1R agonists or glucagon-like peptide 1(GLP-1) stimulation. In the absence of agonist or GLP-1, the GLP-1R receptor is not activated and luminescence signal is low. In the presence of agonist or GLP-1, the GLP-1R pathway-activated luminescence can be detected in a dose-dependent manner.
应用说明(Application)
• Screen for agonists that can bind and activate GLP-1R
生长特性(Growth Properties)
Adherent
筛选标记(Selection Marker)
Puromycin (2 μg/mL) + Hygromycin (20 μg/mL)
培养基(Complete Growth Medium)
DMEM medium + 10% FBS
冻存液(Freeze Medium)
Serum-free cell cryopreservation medium
装量(Quantity)
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
存储(Storage)
Frozen in liquid nitrogen.
支原体检测(Mycoplasma Testing)
Negative
无菌检测(Sterility Testing)
Negative
使用说明(Instructions for Use)
See data sheet for detailed culturing and assay protocol.
数据展示
Receptor Assay
Expression analysis of human GLP-1R on Human GLP-1R (Luc) HEK293 Reporter Cell by FACS.
Cell surface staining was performed on Human GLP-1R (Luc) HEK293 Reporter Cell or negative control cell using PE-labeled anti-human GLP-1R antibody.Protocol
Application
Bioactivity analysis of human GLP-1R agonist (RLU).
This reporter cell was incubated with serial dilutions of Tirzepatide (a dual GLP-1R and GIPR agonist). The EC50 of Tirzepatide was approximately 1.11 nM.ProtocolBioactivity analysis of human GLP-1R agonist (FOLD).
This reporter cell was incubated with serial dilutions of Tirzepatide (a dual GLP-1R and GIPR agonist). The max induction fold was approximately 334.81.Protocol
Passage Stability
Passage stability analysis by Signaling Bioassay.
The continuously growing Human GLP-1R (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of Tirzepatide (a dual GLP-1R and GIPR agonist). Tirzepatide stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 8-24.Protocol
用户评价 发表评论
